^
Association details:
| Biomarker: | ALK rearrangement |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | Tyrosine kinase inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Tyrosine Kinase Inhibitors as a Treatment of Symptomatic CNS Metastases in Oncogene-Driven NSCLC
Published date:
09/03/2020
Excerpt:
In conclusion, upfront use of next-generation EGFR TKIs and ALK TKIs in patients with EGFR-mutant and ALK-rearranged NSCLC with brain metastases is of value in multifocal, large-volume, and symptomatic intracranial tumors; their use in patients with symptomatic CNS metastases is associated with reasonable intracranial activity and symptomatic improvement.
DOI:
10.1155/2020/1980891
